Effects of il-1β-blocking therapies in type 2 diabetes mellitus: A quantitative systems pharmacology modeling approach to explore underlying mechanisms

CPT: Pharmacometrics and Systems Pharmacology

Volumn 3, Issue 6, 2014, Pages

  Palmer R ^a   Nyman, E ^a,b   Penney, M ^c   Marley, A ^d   Cedersund, G ^b   Agoram, B ^c  

^a MathCore Engineering AB   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c MEDIMMUNE   (United States)

^d ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; INTERLEUKIN 1BETA; PROINSULIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

APOPTOSIS; ARTICLE; CELL DIVISION; CLINICAL STUDY; DIET RESTRICTION; DISEASE COURSE; EX VIVO STUDY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET CELL FUNCTION; PREDICTION; PRIORITY JOURNAL; SIMULATION; STEADY STATE;

EID: 84903772139     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2014.16     Document Type: Article

References (37)

1. Donath, M.Y., Dalmas, É., Sauter, N.S. & Böni-Schnetzler, M. Inflammation in obesity and diabetes: islet dysfunction and therapeutic opportunity. Cell Metab. 17, 860-872 (2013).
2. Böni-Schnetzler, M. et al. Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta -cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. J. Clin. Endocrinol. Metab. 93, 4065-4074 (2008).
3. Maedler, K. et al. Low concentration of interleukin-1beta induces FLICE-inhibitory proteinmediated beta-cell proliferation in human pancreatic islets. Diabetes 55, 2713-2722 (2006).
4. Maedler, K. et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J. Clin. Invest. 110, 851-860 (2002).
5. Larsen, C.M. et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356, 1517-1526 (2007).
6. Larsen, C.M., Faulenbach, M., Vaag, A., Ehses, J.A., Donath, M.Y. & Mandrup-Poulsen, T. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 32, 1663-1668 (2009).
7. Cavelti-Weder, C. et al. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care 35, 1654-1662 (2012).
8. Rissanen, A., Howard, C.P., Botha, J. & Thuren, T.. Effect of anti-IL-1βantibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial. Diabetes. Obes. Metab. (2012).
9. van Asseldonk, E.J., Stienstra, R., Koenen, T.B., Joosten, L.A., Netea, M.G. & Tack, C.J. Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study. J. Clin. Endocrinol. Metab. 96, 2119-2126 (2011).
10. Ridker, P.M. et al.; CANTOS Pilot Investigative Group. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: A phase IIb randomized, placebo-controlled trial. Circulation 126, 2739-2748 (2012).
11. Sloan-Lancaster, J. et al. Double-blind, randomized study evaluating the glycemic and antiinflammatory effects of subcutaneous LY2189102, a neutralizing IL-1β antibody, in patients with type 2 diabetes. Diabetes Care 36, 2239-2246 (2013).
12. Ajmera, I., Swat, M., Laibe, C., Novère, N.L. & Chelliah, V. The impact of mathematical modeling on the understanding of diabetes and related complications. CPT. Pharmacometrics Syst. Pharmacol. 2, e54 (2013).
13. Brännmark, C. et al. Insulin signaling in type 2 diabetes: Experimental and modeling analyses reveal mechanisms of insulin resistance in human adipocytes. J. Biol. Chem. 288, 9867-9880 (2013).
14. König, M. & Holzhütter, H.G. Kinetic modeling of human hepatic glucose metabolism in type 2 diabetes mellitus predicts higher risk of hypoglycemic events in rigorous insulin therapy. J. Biol. Chem. 287, 36978-36989 (2012).
15. Dalla Man, C., Rizza, R.A. & Cobelli, C. Meal simulation model of the glucose-insulin system. IEEE Trans. Biomed. Eng. 54, 1740-1749 (2007).
16. Topp, B., Promislow, K., deVries, G., Miura, R.M. & Finegood, D.T. A model of beta-cell mass, insulin, and glucose kinetics: pathways to diabetes. J. Theor. Biol. 206, 605-619 (2000).
17. Ribbing, J., Hamrén, B., Svensson, M.K. & Karlsson, M.O. A model for glucose, insulin, and beta-cell dynamics in subjects with insulin resistance and patients with type 2 diabetes. J. Clin. Pharmacol. 50, 861-872 (2010)
18. de Winter, W. et al. A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus. J. Pharmacokinet. Pharmacodyn. 33, 313-343 (2006).
19. De Gaetano, A. et al. Mathematical models of diabetes progression. Am. J. Physiol. Endocrinol. Metab. 295, E1462-E1479 (2008).
20. Hardy, T., Abu-Raddad, E., Porksen, N. & De Gaetano, A. Evaluation of a mathematical model of diabetes progression against observations in the Diabetes Prevention Program. Am. J. Physiol. Endocrinol. Metab. 303, E200-E212 (2012).
21. Hamrén, B., Björk, E., Sunzel, M. & Karlsson, M. Models for plasma glucose, HbA1c, and hemoglobin interrelationships in patients with type 2 diabetes following tesaglitazar treatment. Clin. Pharmacol. Ther. 84, 228-235 (2008).
22. Lledó-García, R., Kalicki, R.M., Uehlinger, D.E. & Karlsson, M.O. Modeling of red blood cell life-spans in hematologically normal populations. J. Pharmacokinet. Pharmacodyn. 39, 453-462 (2012).
23. Börjesson, A. & Carlsson, C. Altered proinsulin conversion in rat pancreatic islets exposed long-term to various glucose concentrations or interleukin-1beta. J. Endocrinol. 192, 381-387 (2007).
24. Hostens, K. et al. Exposure of human islets to cytokines can result in disproportionately elevated proinsulin release. J. Clin. Invest. 104, 67-72 (1999)
25. Butler, A.E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R.A. & Butler, P.C. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52, 102-110 (2003).
26. Rahier, J., Guiot, Y., Goebbels, R.M., Sempoux, C. & Henquin, J.C. Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes. Obes. Metab. 10 (suppl. 4), 32-42 (2008).
27. Spinas, G.A., Palmer, J.P., Mandrup-Poulsen, T., Andersen, H., Nielsen, J.H. & Nerup, J. The bimodal effect of interleukin 1 on rat pancreatic beta-cells-stimulation followed by inhibition-depends upon dose, duration of exposure, and ambient glucose concentration. Acta Endocrinol. (Copenh). 119, 307-311 (1988).
28. Chang, D.M., Chang, S.Y., Yeh, M.K. & Lai, J.H. The pharmacokinetics of interleukin-1 receptor antagonist in Chinese subjects with rheumatoid arthritis. Pharmacol. Res. 50, 371-376 (2004).
29. Lachmann, H.J. et al. In vivo regulation of interleukin 1beta in patients with cryopyrinassociated periodic syndromes. J. Exp. Med. 206, 1029-1036 (2009).
30. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352, 837-853 (1998).
31. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352, 854-865 (1998).
32. Frey, N., Laveille, C., Paraire, M., Francillard, M., Holford, N.H. & Jochemsen, R. Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation. Br. J. Clin. Pharmacol. 55, 147-157 (2003).
33. Salehi M., Aulinger, B.A. & D'Alessio, D.A. Targeting beta-cell mass in type 2 diabetes: Promise and limitations of new drugs based on incretins. Endocr. Rev. 29, 367-379 (2008).
34. Bunck, M.C. et al. Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care 34, 2041-2047 (2011).
35. Liu, D., Lon, H.K., Dubois, D.C., Almon, R.R. & Jusko, W.J. Population pharmacokinetic pharmacodynamic-disease progression model for effects of anakinra in Lewis rats with collagen-induced arthritis. J. Pharmacokinet. Pharmacodyn. 38, 769-786 (2011).
36. Earp, J.C., Dubois, D.C., Almon, R.R. & Jusko, W.J. Quantitative dynamic models of arthritis progression in the rat. Pharm. Res. 26, 196-203 (2009).
37. Böni-Schnetzler, M. & Donath, M.Y. Increased IL-1β activation, the culprit not only for defective insulin secretion but also for insulin resistance? Cell Res. 21, 995-997 (2011).